Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Helix Biopharma Corp T.HBP

Alternate Symbol(s):  HBPCF

Healthcare Biotechnology
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant... see more

Recent & Breaking News (TSX:HBP)

Helix Biopharma Corp. Announces Issuance of U.S. Patent

TheNewsWire 4 days ago

Helix BioPharma Corp. Enters into Non-Binding Letter of Intent to Acquire Laevoroc Group's Oncology Assets

TheNewsWire 13 days ago

Helix BioPharma Corp. Attends World ADC San Diego

TheNewsWire November 11, 2024

Helix Biopharma Corp. Announces CFO and Corporate Secretary Resignation

TheNewsWire November 8, 2024

Canadian Investment Regulatory Organization Trade Resumption - HBP

Canada NewsWire April 1, 2024

Canadian Investment Regulatory Organization Trading Halt - HBP

Canada NewsWire March 28, 2024

Helix BioPharma Corp. Reports Voting Results

TheNewsWire January 18, 2024

Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results

TheNewsWire December 14, 2023

Helix Biopharma Corp. Announces Fiscal 2023 Year-End Results

TheNewsWire October 27, 2023

Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

TheNewsWire October 10, 2023

Helix BioPharma Corp. Announces Closing of Private Placement of CAD $3 Million and Board Changes

TheNewsWire August 22, 2023

Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results

TheNewsWire June 14, 2023

Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results

TheNewsWire March 15, 2023

Helix Biopharma Corp. Reports Voting Results

TheNewsWire January 24, 2023

Helix Biopharma Corp. Announces Grant & Cancellation of Stock Options

TheNewsWire January 9, 2023

Helix BioPharma Corp. Announces Fiscal 2023 First Quarter Results

TheNewsWire December 14, 2022

Helix Biopharma Corp. Announces Board & Management Changes

TheNewsWire December 8, 2022

Helix Biopharma Corp. Closes Private Placement of CAD $4.62 Million

TheNewsWire November 3, 2022

HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results

TheNewsWire November 1, 2022

Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw as Chief Medical Officer

TheNewsWire October 3, 2022